Frasier Syndrome Market to reach USD 383.40 million by 2029,Trends

Frasier syndrome is a rare hereditary syndromic glomerular condition marked by progressive glomerular nephropathy and 46, XY complete gonadal dysgenesis, as well as a significant risk of gonadoblastoma. Fraser syndrome has no known cure at this time. Surgical correction of some of the abnormalities associated with FS may be required, depending on the severity of the anomalies. Symptomatic and supportive treatment is the only other option. Without therapy, the prognosis is determined by the severity of the patient's individual defects, particularly respiratory tract malformations and anal imperforations.

View Detailed Report" https://www.databridgemarketresearch.com/reports/global-frasier-syndrome-market

Frasier syndrome is a sex development abnormality that affects a small number of people. A mutation in Wilms' tumor suppressor gene (WT-1) on chromosome 11p23 causes it. This gene codes for a transcription factor involved in kidney and gonad development. In 46, XY patients, the syndrome is characterized by female external genitalia, streak gonads, and an increased risk of gonadal cancer, primarily gonadoblastoma. The nephrotic syndrome (NS) is a kind of nephropathy caused by focal segmental glomerular sclerosis (FSGS). NS appears in childhood and is resistant to steroid and immunosuppressive therapy.

Data Bridge Market Research analyses that the Frasier syndrome market was valued at USD 298 million in 2021 and is expected to reach USD 383.40 million by 2029, registering a CAGR of 3.20% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Opportunities

Increase in the number of research and development activities       

The market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the Frasier syndrome market growth.

Moreover, the market's growth is fueled by rising technological advancement in diagnostic methods and emerging new markets. These factors will provide beneficial opportunities for the Frasier syndrome market growth.

Some of the major players operating in the Frasier syndrome market are:

F. Hoffmann-La Roche Ltd. (Switzerland)

Mylan N.V. (U.S.)

Teva Pharmaceutical Industries Ltd. (Ireland)

Sanofi (France)

Pfizer Inc. (U.S.)

GlaxoSmithKline plc (U.K.)

Novartis AG (Switzerland)

Merck & Co., Inc. (U.S.)

Allergan (Ireland)

AstraZeneca (U.K.)

Johnson & Johnson Private Limited (U.S.)

Hikma Pharmaceuticals PLC (U.K.)

Bristol-Myers Squibb Company (U.S.)

Bayer AG (Germany)

Boehringer Ingelheim International GmbH. (Germany)

Dr. Reddy's Laboratories Ltd. (India)

Gilead Sciences, Inc. (U.S.)

Amgen Inc. (U.S.)

Eli Lilly and Company (U.S.)

AbbVie Inc. (U.S.)

Lupin (India)

Allergan (Ireland)

Drivers

Rising incidences of Frasier syndrome

The surging incidences of Frasier syndrome is a major factor driving the market's growth rate during the forecast period of 2022-2029. The kidney condition that occurs in early childhood is known as Frasier syndrome. Affects persons have focal segmental glomerulosclerosis, a disorder in which scar tissue grows in some glomeruli, which are small blood arteries in the kidneys that filter waste from the blood. Frasier syndrome is a disorder that often leads to renal failure by adolescence in persons who have it.

Explore More Reports:

https://databridgemarketresearchreports.blogspot.com/2024/04/nasal-spray-market-to-reach-value-of.html

https://databridgemarketresearchreports.blogspot.com/2024/04/bacteriophages-therapy-market-to-reach.html

https://databridgemarketresearchreports.blogspot.com/2024/04/rett-syndrome-market-to-undergo-cagr-of.html

https://databridgemarketresearchreports.blogspot.com/2024/04/kidney-disease-market-would-grow-up-to.html

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market.

Contact Us:

Data Bridge Market Research
Tel: +1-888-389.80-2818 | +44 208 089 1725 | +852 8192 7475
Email: Corporatesales@databridgemarketresearch.com

This release was published on openPR.